Update on options for treatment of metastatic castration-resistant prostate cancer

References

• American Chemical Society Website. Available from: http://www.acs.org/ Accessed on December 10, 2009.
   Google Scholar
• DeVitaVTLawrenceTSRosenbergSACancer Principles and Practice of Oncology8th ed200813921445
   Google Scholar
• Cancer of the prostate Tables and figures #23. 2009 Available from: http://seer.cancer.gov/csr/1975_2006/results_merged/sect_23_prostate.pdf Accessed on December 10, 2009.
   Google Scholar
• LassiKDawsonNAEmerging therapies in castrate-resistant prostate cancerCurr Opin Oncol20092126026519363343
   PubMed Web of Science ®Google Scholar
• AttarRMTakimotoCHGottardisMMcastration-resistant prostate cancer: locking up the molecular escape routesClin Cancer Res200915103251325519447877
   PubMed Web of Science ®Google Scholar
• HeloPCroninAMDanilaDCCirculating prostate tumor cells detected by RT-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survivalClin Chem200955476577319233911
   PubMed Web of Science ®Google Scholar
• ScherHIMorrisMJKellyWKDesign and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working GroupJ Clin Oncol20082671148115918309951
   PubMed Web of Science ®Google Scholar
• BubleyGJCarducciMDahutWEligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working GroupJ Clin Oncol199917113461346710550143
   PubMed Web of Science ®Google Scholar
• HussainMGoldmanBTangenCProstate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916J Clin Oncol200927152450245619380444
   PubMed Web of Science ®Google Scholar
• TrougakosIPGonosESClusterin/apolipoprotein J in human aging and cancerInt J Biochem Cell Biol200234111430144812200037
   PubMed Web of Science ®Google Scholar
• SoAHadaschikBSoweryRThe role of stress proteins in prostate cancerCurr Genom200784252261
   Web of Science ®Google Scholar
• MiyakeHYamanakaKMuramakiMEnhanced expression of the secreted form of clusterin following neoadjuvant hormonal therapy as a prognostic predictor in patients undergoing radical prostatectomy for prostate cancerOncol Rep20051451371137516211311
   PubMed Web of Science ®Google Scholar
• ZellwegerTMiyakeHJulyLVChemosensitization of human renal cell cancer using antisense oligonucleotides targeting the anti-apoptotic gene clusterinNeoplasia20013436036711571636
   PubMed Web of Science ®Google Scholar
• PinsMRFiadjoeJEKorleyFClusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: a preliminary reportProstate Cancer Prostatic Dis20047324324815343364
   PubMed Web of Science ®Google Scholar
• ChiKNHotteSJYuEMature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone vs docetaxel/prednisone in patients with metastatic castration-resistant prostate cancerJ Clin Oncol20092715s Abstract # 5012.
   Google Scholar
• DehdashtiFPicusJMichalskiJMPositron tomographic assessment of androgen receptors in prostatic carcinomaEur J Nucl Med Mol Imaging200532334435015726353
   PubMed Web of Science ®Google Scholar
• LarsonSMMorrisMGuntherITumor localization of 16b-18F-Fluoro-5b-dihydrotestosterone vs 18F-FDG in patients with progressive, metastatic prostate cancerJ Nucl Med200445336637315001675
   PubMed Web of Science ®Google Scholar
• MorrisMJSchoderHSmith-JonesPPilot trial of [18F]fluoro-dihydro-testosterone (FDHT) and [18F]fluoro-2-deoxy-D-glucose (FDG) PET imaging in patients with castrate metastatic prostate cancer (CMPC)Proc Am Soc Clin Oncol (2006 Prostate Cancer Symposium); Abstract #144.
   Google Scholar
• National Institutes of Health Clinical Trials. 2009Available from: http://clinicaltrials.gov/ Accessed on December 10, 2009.
   Google Scholar
• ScherHIBeerTMHiganoCSAntitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC)J Clin Oncol20092715s Abstract #5011.
   Google Scholar
• de BonoJSScherHIMontgomeryBRCirculating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancerClin Cancer Res200814196302630918829513
   PubMed Web of Science ®Google Scholar
• Groves-KirkbyNBiomarkers: Circulating tumor cells in prostate cancerNature Rev Urol200965238
   Google Scholar
• TannockIFde WitRBerryWDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerN Engl J Med2004351151502151215470213
   PubMed Web of Science ®Google Scholar
• BertholdDRPondGde WitRDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival of Tax 327J Clin Oncol20072518s Abstract #5005.
   Google Scholar
• PetrylakDPTangenCMHussainMHDocetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancerN Engl J Med2004351151513152015470214
   PubMed Web of Science ®Google Scholar
• KoletskyAJGuerraMLKronishLPhase II study of vinorelbine and low-dose docetaxel in chemotherapy-naive patients with hormone-refractory prostate cancerCancer J20039428629212967139
   PubMed Web of Science ®Google Scholar
• Di LorenzoGPizzaCAutorinoRWeekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancerEur Urol200446671271615548437
   PubMed Web of Science ®Google Scholar
• HahnNMMarshSFisherWHoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysisClin Cancer Res200612206094609917062685
   PubMed Web of Science ®Google Scholar
• VaishampayanUNHeilbrunHEliasonJPhase II trial of docetaxel and capecitabine combination in metastatic androgen independent prostate cancer (AIPC)Proc Am Soc Clin Oncol (2007 Prostate Cancer Symposium); Abstract # 239.
   Web of Science ®Google Scholar
• DahutWLGulleyJLArlenPMRandomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancerJ Clin Oncol200422132532253915226321
   PubMed Web of Science ®Google Scholar
• OhWKHalabiSKellyKWA phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813Cancer200398122592259814669278
   PubMed Web of Science ®Google Scholar
• BrausiMJonesWGFossaSDHigh dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary GroupEur J Cancer199531A10162216267488412
   PubMed Web of Science ®Google Scholar
• PetrioliRPaolelliLFranciniEWeekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancerUrology200769114214617270637
   PubMed Web of Science ®Google Scholar
• SchwartzGGOelerTAUskokovicMRHuman prostate cancer cells: Inhibition of proliferation by vitamin D analogsAnticancer Res1994143A107710818074453
   PubMed Web of Science ®Google Scholar
• BeerTMRyanCWVennerPMDouble-blinded randomized study of high dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT investigatorsJ Clin Oncol200725666967417308271
   PubMed Web of Science ®Google Scholar
• ChaoDTKorsmeyerSJBCL-2 FAMILY: Regulators of cell deathAnn Rev Immunol19981613954199597135
   PubMed Web of Science ®Google Scholar
• TolcherAWKuhnJSchwartzGA phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone refractory prostate cancerClin Cancer Res200511103854386115897586
   PubMed Web of Science ®Google Scholar
• SternbergCNDumezHVan PoppelHDocetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancerAnn Oncol20092071264126919297314
   PubMed Web of Science ®Google Scholar
• MiyakeHHaraIKamidonoSResistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expressionOncol Rep200310246947312579291
   PubMed Web of Science ®Google Scholar
• ChiKNEisenhauerEFazliLA phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2’-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancerJ Natl Cancer Inst200597171287129616145049
   PubMed Web of Science ®Google Scholar
• ManiSMacapinlaccMJrGoelSThe clinical development of new mitotic inhibitors that stabilize the microtubuleAnticancer Drug2004156553558
   Google Scholar
• GalskyMDSmallEJOhWKMulti-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancerJ Clin Oncol20052371439144615735119
   PubMed Web of Science ®Google Scholar
• HussainMTangenCLaraPIxabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111J Clin Oncol200523348724872916314632
   PubMed Web of Science ®Google Scholar
• RosenbergJEKellyWKMichaelsonMDA randomized phase II study of ixabepilone (Ix) or mitoxantrone and prednisone (MP) in patients with taxane (T)-resistant hormone refractory prostate cancer (HRPC)J Clin Oncol20052316s Abstract # 4566.
   Google Scholar
• ChiKNBeardsleyEKVennerPMA phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxelJ Clin Oncol20082615s Abstract # 5166.
   Google Scholar
• JordanMAKamathKMannaTThe primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growthMol Cancer Ther2005471086109516020666
   PubMed Web of Science ®Google Scholar
• de BonoJSMarotoPCalvoEPhase II study of eribulin mesylate (E7389) in patients (patients) with metastatic castration-resistant prostate cancer (CRPC) stratified by prior taxane therapyProc Am Soc Clin Oncol (2009 Genitourinary Cancer Symposium); Abstract # 166.
   Google Scholar
• NamSKimDChengJQAction of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cellsCancer Res2005659185918916230377
   PubMed Web of Science ®Google Scholar
• EdwardsJKrishnaNSWittonCJGene amplifications associated with the development of hormone-resistant prostate cancerClin Cancer Res20039145271528114614009
   PubMed Web of Science ®Google Scholar
• TatarovOMitchellTJSeywrightMSRC family kinase activity is up-regulated in hormone-refractory prostate cancerClin Cancer Res200915103540354919447874
   PubMed Web of Science ®Google Scholar
• KoreckijTNguyenHBrownLGDasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysisBr J Cancer20091012636819603032
   PubMed Web of Science ®Google Scholar
• YuEYWildingGPosadasEPhase II study of dasatinib in patients with metastatic castration-resistant prostate cancerClin Cancer Res20091523OF18
   Web of Science ®Google Scholar
• HiganoCSaadFSomerBA phase III trial of GVAX immunotherapy for prostate cancer vs docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC)Proc Am Soc Clin Oncol (2009 Genitourinary Cancer Symposium); Abstract # LBA150.
   Google Scholar
• SmallEDemkovTGerritsenWRA phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel vs docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC)Proc Am Soc Clin Oncol (2009 Genitourinary Cancer Symposium); Abstract # 7.
   Google Scholar
• TannockIFde WitRBerryWRChemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end pointsJ Clin Oncol1996146175617648656243
   PubMed Web of Science ®Google Scholar
• KantoffPWHalabiSConawayMHydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 studyJ Clin Oncol19991782506251310561316
   PubMed Web of Science ®Google Scholar
• BerryWDakhilSModianoMPhase III study of mitoxantrone plus low dose prednisone vs low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancerJ Urol200216862439244312441935
   PubMed Web of Science ®Google Scholar
• GarmeyEGSartorOHalabiSSecond-line chemotherapy for advanced hormone-refractory prostate cancerClin Adv Hematol Oncol20086211812212713218347563
   PubMedGoogle Scholar
• GeorgeDJHalabiSShepardTFPrognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480Clin Cancer Res2001771932193611448906
   PubMed Web of Science ®Google Scholar
• Di LorenzoGFiggWDFossaSDCombination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: A phase 2 studyEur Urol20085451089109618276061
   PubMed Web of Science ®Google Scholar
• DahutWLScriptureCPosadasEA phase II clinical trial of sorafenib in androgen-independent prostate cancerClin Cancer Res20084120921418172272
   PubMed Web of Science ®Google Scholar
• LatifTWoodLConnellCPhase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC)Invest New Drugs2005231798415528984
   PubMed Web of Science ®Google Scholar
• SternbergCNWhelanPHetheringtonJPhase III trial of satraplatin, an oral platinum plus prednisone vs prednisone alone in patients with hormone-refractory prostate cancerOncology20056812915741753
   PubMed Web of Science ®Google Scholar
• SartorAOPetrylakDPWitjesJASatraplatin in patients with advanced hormone-refractory prostate cancer (HRPC): Overall survival (OS) results from the phase III satraplatin and prednisone against refractory cancer (SPARC) trialJ Clin Oncol20082615s Abstract #5003.
   Google Scholar
• BeardsleyEKSaadFEiglBA phase II study of patupilone in patients (patients) with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxelJ Clin Oncol20092715s Abstract # 5139.
   Google Scholar
• RosenbergJEWeinbergVKellyKWActivity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisoneCancer2007110355656317577218
   PubMed Web of Science ®Google Scholar
• ThakkarSGChoueiriTKGarciaJAEndothelin receptor antagonists: Rationale, clinical development, and role in prostate cancer therapeuticsCurr Oncol Rep20068210811316507220
   PubMedGoogle Scholar
• NelsonJBHedicanSPGeorgeDJIdentification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostateNature Med1995199449497585222
   PubMed Web of Science ®Google Scholar
• CarducciMASaadFAbrahamssonPA phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancerCancer20071101959196617886253
   PubMed Web of Science ®Google Scholar
• AttardGBelldegrunASde BonoJSSelective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancerBJU Int20059691241124616287438
   PubMed Web of Science ®Google Scholar
• TranCOukSCleggNJDevelopment of a second-generation antiandrogen for treatment of advanced prostate cancerScience2009324592878779019359544
   PubMed Web of Science ®Google Scholar
• SmallEJSchellhammerPFHiganoCSPlacebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancerJ Clin Oncol200624193089309416809734
   PubMed Web of Science ®Google Scholar